Medicine and manufacturing technology provider Novanta (NASDAQ: NOVT) beat Wall Street’s revenue expectations in Q2 CY2026, with sales up 10.3% year on year to $265.8 million. On top of that, next quarter’s revenue guidance ($302 million at the midpoint) was surprisingly good and 14.9% above what analysts were expecting. Its non-GAAP profit of $0.89 per share was 7.2% above analysts’ consensus estimates.

Is now the time to buy NOVT? Find out in our full research report (it’s free for active Edge members).

StockStory’s Take

Novanta's second quarter was marked by broad-based organic growth across all business units and a favorable response from the market. Management attributed the strong results to both an acceleration in new product revenue—up more than 50% year-over-year—and operational improvements, including factory consolidations. CEO Matthijs Glastra highlighted that all business units grew organically and pointed to increased customer demand in precision robotics, AI-driven manufacturing, and minimally invasive surgery as significant contributors to quarterly performance.

Looking ahead, Novanta’s raised guidance is underpinned by several factors discussed on the call, including momentum from its largest-ever acquisition, Riverpoint Medical, and expanding demand in automation and medical end markets. CFO Robert Buckley emphasized the expected accretion from Riverpoint Medical to both revenue and margins, while noting that manufacturing site rationalizations and increased capacity for air bearing spindles are expected to further support profitability. Management cautioned that while the macroeconomic environment remains complex, the company’s backlog and customer commitments give them confidence in achieving their updated targets.

Key Insights from Management’s Remarks

Management identified the combination of robust new product adoption, successful acquisition execution, and operational streamlining as primary drivers of recent performance and the company’s improved outlook.

• New product traction: Revenue from newly launched products grew over 50% year-over-year, now comprising nearly 29% of sales. Management credited this surge to strong demand in precision robotics, advanced surgery equipment, and AI-driven manufacturing solutions.
• Riverpoint Medical acquisition: The recently closed acquisition of Riverpoint Medical, Novanta’s largest to date, is expected to accelerate the company’s shift toward recurring medical consumable revenue and expand exposure to high-growth procedures like sports medicine and cardiovascular surgery. Management described Riverpoint as immediately accretive to growth, margins, and earnings.
• Manufacturing consolidation: Novanta finalized the closure of two manufacturing sites and announced two additional closures by early 2027 to further regionalize production. This ongoing restructuring aims to simplify operations, reduce costs, and mitigate risks from global trade disruptions.
• AI and automation demand: The Automation Enabling Technologies segment saw 12% growth, driven by the adoption of proprietary laser subsystems and robotics components in high-precision manufacturing and AI data center infrastructure. Orders for servo drives supporting humanoid robotics entered a new phase, moving beyond prototyping.
• Margin dynamics: While gross margin improved 100 basis points year-over-year, temporary costs from operational transitions and a shift in product mix weighed on the Medical Solutions segment. Management expects margins to recover in the second half as integration and manufacturing moves are completed.

Drivers of Future Performance

Novanta’s outlook for the coming quarters is centered on sustained demand in automation and medical markets, integration benefits from Riverpoint Medical, and ongoing cost optimization measures.

• Riverpoint Medical integration: Management expects Riverpoint Medical to immediately contribute to revenue growth and margin expansion, particularly through recurring sales of medical consumables and higher exposure to minimally invasive surgical procedures.
• AI and robotics adoption: The company anticipates continued momentum in its automation segment, driven by increased demand for robotics used in AI data centers, high-precision manufacturing, and semiconductor applications. Orders for humanoid robotics components are ramping past initial prototyping phases, although management noted that the scale-up remains in early stages.
• Operational restructuring: The acceleration of manufacturing site closures and regionalization of production is projected to further reduce complexity and support gross margin improvement in 2027. However, management cited ongoing trade tariffs and supply chain costs as headwinds that could temper margin gains if not fully offset by pricing or productivity improvements.

Catalysts in Upcoming Quarters

In the coming quarters, our analysts will monitor (1) the pace and financial impact of Riverpoint Medical integration, (2) the execution and cost savings from ongoing manufacturing site closures, and (3) continued momentum in AI-driven automation and robotics, especially as large orders transition from prototyping to broader deployment. The evolution of tariff-related headwinds and product mix changes will also be key indicators to watch.

Novanta currently trades at $164.22, up from $153.12 just before the earnings. Is the company at an inflection point that warrants a buy or sell? See for yourself in our full research report (it’s free).

Stocks That Trumped Tariffs

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.